
Six ABX Marketing Challenges For B2B SaaS And Their Solutions
Salman Shahid, CEO at OXO Packaging.
With advancements in technology, most B2B buyers look for personalized solutions that can help their business grow exponentially. There are different strategies your business can implement to offer customized services, and one highly effective strategy is account-based experience (ABX) marketing.
ABX marketing allows B2B SaaS companies to offer highly tailored strategies to engage high-value accounts and maximize ROI. However, your business can encounter several challenges when implementing this strategy. Read on to explore six of these challenges and ways to solve them.
As a B2B SaaS company, audience analysis is crucial for your business when implementing an ABX marketing strategy. It is important to stay ahead of the curve and outrank your competitors when landing clients. You can identify the gaps within audience research and offer experiences that your competitors are failing to provide.
There are different automated tools to help you perform a reliable audience analysis. Using these tools, you can find the strengths and weaknesses of your competitors and implement strategies in accordance to offer more value to your customers.
For example, you can use solutions such as Kantar Marketplace or System1 Group to get data-driven audience insights. The more relevant data you have, the easier you'll find it to craft and implement your ABX marketing strategy and get the results you want.
As a business, you should take into consideration the resources, budget, time and staff required before defining the approach to your ABX marketing strategy. Generally, there are three approaches your business can implement to provide tailored marketing experiences to your accounts:
• 1:1 Approach: This offers hyper-personalized experiences to high-value clients from the list of ICPs.
• 1:Few Approach: This focuses on tailored experiences to more than one account.
• 1:Many Approach: This provides an all-inclusive experience to all accounts on the ICP list.
The best approach is to start with a 1:Few or 1:Many approach, as these two are more time and resource-efficient.
Data discrepancies can occur within the different departments of your business. For example, there can be a disagreement between your sales and marketing teams about lead qualification, defining metrics and utilizing different tools.
Disagreements like these can result in a mismatch of goals and blur the goalposts to stop you from getting the desired outcomes. And you can eventually lose accounts and run into data compliance challenges if discrepancies aren't avoided.
Using an integrated CRM for ABX marketing can minimize data discrepancies and ensure smooth and accurate results for your campaigns. For example, you can choose from popular options like HubSpot, Typeform and Zoho to save the data accurately.
You can also use FOSS solutions like SuiteCRM for your ABX marketing campaigns. Before finalizing your CRM, ensure you get all your teams on the same page to avoid data discrepancies and get desired results faster.
ABX marketing demands highly customized content, which requires more marketing resources. This can ultimately cause a strain on the budget your finance team has allocated. Creating personalized content for accounts, without automation, can slow down the efficiency of your business model.
Using AI automation can help your business create a comprehensive and detailed content library that can cater to every account.
Leveraging AI can help your business model tailor the content specifically to the individual account's needs. AI tools can analyze heaps of data to understand the needs of every account and can group similar ones. This automation can help your business create personalized marketing collateral more accurately and efficiently.
For example, you can use solutions like Watson Campaign Automation or Salesforce Marketing Cloud to automate your ABX marketing campaigns. You can also use these types of tools to send personalized messages in bulk or track the performance of your campaigns more easily.
Results in B2B SaaS often take time, and it can be hard to measure immediate success when implementing your ABX marketing strategy. This is why employing KPIs is crucial to evaluate account-based experience success.
Implement AI within your business model, or use tools such as Simple Analytics, ClickUp and Turtl to measure engagement metrics and pipeline velocity. Real-time data tracking can help you to take result-driven actions and adjust your KPIs according to your needs.
KPIs powered by detailed analytics can help your business optimize your ABX marketing strategies and offer better experiences to your accounts. More reliable data will also help you make informed future ABX marketing decisions.
Scalability in an ABX marketing strategy becomes an issue as you have to offer personalization to each account individually. A 1:1 strategy is not as scalable as the other two because it requires more resources for personalized experiences for your accounts.
To achieve scalability, you can prioritize high-value ICPs and offer personalized resources to these accounts. Once these valued customers are nurtured, gradually introduce more accounts to these personalized changes.
Microsoft's strategy of 1:Few for making Copilot a household GenAI solution for enterprises is a great example of making ABX marketing scalable in the long run.
In May 2023, Microsoft introduced the Early Access Copilot Program for 600 enterprise customers. After initial success, the program was made available for enterprise accounts worldwide. Microsoft's 1:Few approach eventually got scaled into 1:Many as it provided results that Microsoft had expected.
In August 2024, Microsoft published the success story of Insight Enterprises. This report showed how Insight Enterprises was able to streamline business operations using Microsoft Copilot—a testament to Microsoft's ABX marketing success.
With the right ABX marketing strategy, your business can improve its marketing and achieve sales success faster. Test ABX marketing strategies to offer personalized solutions to high-value accounts. If you can overcome the challenges faced in ABX marketing by implementing the solutions discussed above, you can win goals faster in the long run.
Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23-05-2025
- Yahoo
Autobahn Therapeutics Announces Presentation of ABX-002 Phase 1 Clinical Results at the 2025 ASCP Annual Meeting
Poster presentation to highlight Phase 1 results that support ABX-002 Phase 2 development as an adjunctive treatment for major depressive disorder and bipolar disorder depression SAN DIEGO, May 23, 2025--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the company will present the clinical results from its completed Phase 1 trial of ABX-002 at the 2025 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 27-30, 2025, in Scottsdale, AZ. ABX-002 is a highly potent, oral, thyroid hormone beta receptor (TRβ) selective agonist designed to enhance the CNS benefits of thyroid hormone biology for patients suffering from major depressive disorder (MDD), bipolar disorder depression, and other affective illnesses. "We are excited to share the Phase 1 findings at ASCP, which demonstrated a favorable safety and tolerability profile and enhanced CNS target engagement with ABX-002, and support its evaluation in the ongoing Phase 2 trials in major depressive disorder and bipolar depression," said Gudarz Davar, M.D., Executive Vice President, Head of Research and Development for Autobahn. "Despite availability of existing therapies, many individuals with MDD and bipolar depression struggle to achieve adequate relief. Our team remains deeply committed to developing novel, CNS-targeted treatments that we believe have the potential to meaningfully improve the lives of those affected by these debilitating conditions." Results from the completed Phase 1 trial of ABX-002 in healthy volunteers demonstrated ABX-002 was safe and well tolerated, with no serious adverse events observed. Additionally, ABX-002 demonstrated dose proportional PK and clinical evidence of CNS target engagement consistent with brain-activating thyroid effects, helping inform Phase 2 dose selection. The company is currently evaluating ABX-002 as a potential adjunctive treatment for people with major depressive disorder in the ongoing AMPLIFY Phase 2 trial and as a potential adjunctive treatment for bipolar depression in a separate ongoing Phase 2 trial. Details for the poster presentation can be found below: Title: A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Novel Thyromimetic ABX-002 in Healthy Adult ParticipantsDate: Thursday, May 29, 2025Time: 11:30 a.m. – 1:15 p.m. MTPresenter: Bridgette Franey, M.D., Senior Medical Director, Global Medical Lead - Clinical Development, Autobahn TherapeuticsLocation: Fairmont Scottsdale Princess, Scottsdale, AZ The abstract and additional details can be found on the 2025 ASCP annual meeting website. About Autobahn TherapeuticsAutobahn Therapeutics is a biotechnology company developing a portfolio of neuropsychiatric and neuroimmunologic clinical candidates leveraging its brain-targeting chemistry platform. Autobahn aims to unlock new therapeutic opportunities through precision tuning of CNS exposure, pursuing validated clinical and biologic targets, and guiding development with biomarkers. The company's pipeline is led by ABX-002, a thyroid hormone receptor beta (TRβ) agonist being developed as a potential adjunctive treatment for people with major depressive disorder and bipolar disorder depression. Autobahn Therapeutics is based in San Diego. For more information, visit About ABX-002ABX-002 is an orally administered, potent and selective thyroid hormone beta receptor (TRβ) agonist designed to enhance the CNS benefits of thyroid hormone biology while also reducing the peripheral liabilities of synthetic thyroid hormone (e.g., triiodothyronine, T3), a treatment which has shown efficacy in numerous placebo-controlled human studies across MDD and bipolar disorder depression. Thyroid hormone agonism has demonstrated activity on cellular energy metabolism pathways, which play an important role on the regulation of brain bioenergetics and may be uniquely suited to address symptoms of atypical depression, a highly prevalent and underserved sub-population of MDD. In nonclinical and clinical studies, ABX-002 has demonstrated optimized PK properties, target engagement in brain regions associated with depression, and an attractive safety and tolerability profile. View source version on Contacts Investors: Alex StrausTHRUST Strategic Communicationsalex@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
23-05-2025
- Business Wire
Autobahn Therapeutics Announces Presentation of ABX-002 Phase 1 Clinical Results at the 2025 ASCP Annual Meeting
SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the company will present the clinical results from its completed Phase 1 trial of ABX-002 at the 2025 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 27-30, 2025, in Scottsdale, AZ. ABX-002 is a highly potent, oral, thyroid hormone beta receptor (TRβ) selective agonist designed to enhance the CNS benefits of thyroid hormone biology for patients suffering from major depressive disorder (MDD), bipolar disorder depression, and other affective illnesses. 'We are excited to share the Phase 1 findings at ASCP, which demonstrated a favorable safety and tolerability profile and enhanced CNS target engagement with ABX-002, and support its evaluation in the ongoing Phase 2 trials in major depressive disorder and bipolar depression,' said Gudarz Davar, M.D., Executive Vice President, Head of Research and Development for Autobahn. 'Despite availability of existing therapies, many individuals with MDD and bipolar depression struggle to achieve adequate relief. Our team remains deeply committed to developing novel, CNS-targeted treatments that we believe have the potential to meaningfully improve the lives of those affected by these debilitating conditions.' Results from the completed Phase 1 trial of ABX-002 in healthy volunteers demonstrated ABX-002 was safe and well tolerated, with no serious adverse events observed. Additionally, ABX-002 demonstrated dose proportional PK and clinical evidence of CNS target engagement consistent with brain-activating thyroid effects, helping inform Phase 2 dose selection. The company is currently evaluating ABX-002 as a potential adjunctive treatment for people with major depressive disorder in the ongoing AMPLIFY Phase 2 trial and as a potential adjunctive treatment for bipolar depression in a separate ongoing Phase 2 trial. Details for the poster presentation can be found below: Title: A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Novel Thyromimetic ABX-002 in Healthy Adult Participants Date: Thursday, May 29, 2025 Time: 11:30 a.m. – 1:15 p.m. MT Presenter: Bridgette Franey, M.D., Senior Medical Director, Global Medical Lead - Clinical Development, Autobahn Therapeutics Location: Fairmont Scottsdale Princess, Scottsdale, AZ The abstract and additional details can be found on the 2025 ASCP annual meeting website. About Autobahn Therapeutics Autobahn Therapeutics is a biotechnology company developing a portfolio of neuropsychiatric and neuroimmunologic clinical candidates leveraging its brain-targeting chemistry platform. Autobahn aims to unlock new therapeutic opportunities through precision tuning of CNS exposure, pursuing validated clinical and biologic targets, and guiding development with biomarkers. The company's pipeline is led by ABX-002, a thyroid hormone receptor beta (TRβ) agonist being developed as a potential adjunctive treatment for people with major depressive disorder and bipolar disorder depression. Autobahn Therapeutics is based in San Diego. For more information, visit About ABX-002 ABX-002 is an orally administered, potent and selective thyroid hormone beta receptor (TRβ) agonist designed to enhance the CNS benefits of thyroid hormone biology while also reducing the peripheral liabilities of synthetic thyroid hormone (e.g., triiodothyronine, T3), a treatment which has shown efficacy in numerous placebo-controlled human studies across MDD and bipolar disorder depression. Thyroid hormone agonism has demonstrated activity on cellular energy metabolism pathways, which play an important role on the regulation of brain bioenergetics and may be uniquely suited to address symptoms of atypical depression, a highly prevalent and underserved sub-population of MDD. In nonclinical and clinical studies, ABX-002 has demonstrated optimized PK properties, target engagement in brain regions associated with depression, and an attractive safety and tolerability profile.
Yahoo
12-05-2025
- Yahoo
Nicole Stavroff of FireMon Spotlighted on the 2025 Women of the Channel List
LENEXA, Kan., May 12, 2025--(BUSINESS WIRE)--FireMon, a leader in network security policy management (NSPM), proudly announced today that CRN®, a brand of The Channel Company, has recognized Nicole Stavroff, VP of Worldwide Channels on the prestigious Women of the Channel list for 2025. This annual CRN list celebrates women from vendors, distributors, solution providers and other channel-focused organizations who make a positive difference in the IT ecosystem. The CRN 2025 Women of the Channel honorees are innovative and strategic leaders committed to advancing channel excellence and supporting the success of their partners and customers. Nicole Stavroff serves as Vice President of Worldwide Channels at FireMon, where she leads global channel strategy and empowers partners to drive growth in network security policy management. With over 28 years of experience in channel leadership, Nicole has transformed FireMon's channel program, revamping the Ignite Partner Program, launching FireMon University, and introducing stackable incentives and strategic sales plays. Under her leadership, FireMon has seen a 600% increase YoY in partner certifications and up to 300% YoY revenue growth across FireMon's top focus partners. The global channel strategy was a key driver in this revenue growth, combining an ABX-ICP go-to-market focus with strategic partner alignment, with both VARs and alliance vendors. Additionally, strengthening field relationships with key alliance partners like Fortinet and "meeting in the middle" across mutual top partners, enabled the channel to deliver a "Better Together" combined solution and increased ROI value to end-user customers. Nicole was recognized on CRN's 2024 Power 100 list for her continued impact and innovation in the channel. "It's an honor to recognize the outstanding accomplishments of these women, who are leaders and change-makers in the IT channel," said Jennifer Follett, VP, U.S. Content and Executive Editor, CRN at The Channel Company. "Each woman spotlighted on this list has shown exceptional dedication to building creative strategies that propel transformation, growth, and success for their organizations and the entire IT channel. We are pleased to spotlight their important contributions and look forward to their future success." "FireMon congratulates Nicole on her well-deserved recognition in CRN's 2025 Women of the Channel list," said Jody Brazil, CEO of FireMon. "Her leadership, strategic vision, and commitment to partner success have played a key role in strengthening our channel program and accelerating global growth. As a 100% channel-driven company, we remain focused on delivering innovation that empowers our partners and customers alike, and Nicole's contributions continue to advance that mission." The 2025 Women of the Channel will be featured in the June issue of CRN Magazine, with online coverage beginning May 12 at About FireMon FireMon's mission is to improve security operations that will, in turn, lead to better security outcomes. FireMon delivers industry-leading security policy management, cloud security, and asset management solutions. Our platform is the only real-time solution that reduces firewall and cloud security policy-related risks, manages policy changes, and enforces compliance. FireMon's Cloud Defense (formerly DisruptOps) is the only distributed cloud security offering that detects and responds to issues in the fast-paced public cloud environments. Our cloud-based Asset Management solution (formerly Lumeta) scans entire infrastructures to identify everything in the environment and provide valuable insights into how it's all connected. Learn more at and the FireMon Blog. About The Channel Company The Channel Company (TCC) is the global leader in channel growth for the world's top technology brands. We accelerate success across strategic channels for tech vendors, solution providers, and end users with premier media brands, integrated marketing and event services, strategic consulting, and exclusive market and audience insights. TCC is a portfolio company of investment funds managed by EagleTree Capital, a New York City-based private equity firm. For more information, visit Follow The Channel Company: X and LinkedIn © 2025. CRN is a registered trademark of The Channel Company, Inc. All rights reserved. View source version on Contacts Media Contact Sarah ShkargiEmail: Sarah@ The Channel Company Contact: Kristin DaSilvaThe Channel Companykdasilva@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data